Associations Between Antiprotozoal Treatments and Reduced Mortality Across Populations Suggest That Protozoal Colonization May Contribute Significantly to Human Mortality and Age-Related Morbidity

Ariel Israel[1,2]* MD, PhD, Abraham Weizman MD[3], Sarah Israel MD[4], Shai Ashkenazi MD, MSc[5,6], Eytan Ruppin[7], Shlomo Vinker MD, MHA[1], Eli Magen MD[8], Eugene Merzon MD, MPH[1,5]

Affiliations:

[1] Leumit Research Institute, Leumit Health Services, 23 Sprinzak St., Tel Aviv 6473817, Israel

[2] Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University; Ramat Aviv, Tel Aviv 6997801, Israel

[3] Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center, and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel Aviv University, 6997801, Israel

[4] Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, P.O. Box 12000, Jerusalem 9112001, Israel

[5] Adelson School of Medicine, Ariel University, Ariel 40700, Israel

[6] Department of Infectious Diseases, Schneider Children's Medical Center, 14 Kaplan St., Petah Tikva 4920235, Israel

[7] Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

[8] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, Derech HaRofe 7, Ashdod 7747629, Israel

Corresponding author:

Ariel Israel, MD, PhD

Leumit Research Institute

Leumit Health Services

23 Sprinzak St., Tel Aviv 6473817, Israel

Email: **aisrael@leumit.co.il**

ABSTRACT:

To identify medications with the potential to increase human lifespan, we conducted a systematic screening of electronic health records from a national health organization, comparing medications consumed over the preceding decade by individuals over 60 who outlived the average life expectancy with those consumed by matched individuals who died before reaching it. This screen identified two antiprotozoal agents, atovaquone-proguanil and mefloquine, as strongly associated with increased longevity (odds ratios for 10-year mortality: 0.43 and 0.32; FDR = 0.0002 and 0.0001, respectively). We validated these associations in the U.S.-based TriNetX federated network, confirming that these two antiprotozoals, along with nirmatrelvir-ritonavir—a medication used to prevent severe COVID-19 outcomes and possessing antiprotozoal properties—were associated with significantly reduced mortality and a lower incidence of major age-related conditions, including diabetes mellitus, cardiovascular and cerebrovascular diseases, renal insufficiency, dementia, pulmonary disease, liver disease, and malignancies. Across both populations, antiprotozoal exposure was also associated with increased risks of specific adverse outcomes, notably hearing loss, Sjögren's syndrome, and lichen planus. The consistent observation of both benefits and risks across independent populations supports the biological plausibility of these effects and argues against confounding by indication or underdiagnosis. Taken together, these findings suggest that elimination of protozoal parasites—notably *Toxoplasma gondii*—may significantly reduce human age-related morbidity and mortality while increasing the risk of specific auditory, ophthalmic, and dermatologic complications. These results offer promising new avenues to extend human lifespan and promote healthy aging through targeted antimicrobial interventions.

Abbreviations

A-P: atovaquone-proguanil

BMI: Body Mass Index

BP: Blood pressure

EHR: Electronic health records

FDR: False Discovery Rate

HCO: Healthcare organizations

HR: Hazards Ratio

ICD: International Classification of Diseases

LHS: Leumit Health Services

N-R: nirmatrelvir-ritonavir

OR: Odds Ratio

PSM: Propensity score matching

SES: Socioeconomic status

SMD: Standardized Mean Difference

Introduction

Understanding the long-term effects of medication use is a central goal of pharmacoepidemiology and drug repurposing research. Many drugs approved for specific indications may exert previously unrecognized effects—either beneficial or harmful—on broader aspects of human health. Identifying such off-target effects is particularly valuable when they influence chronic disease risk or overall survival. Medications that promote general health would, in principle, be expected to increase lifespan. By examining prior medication use in individuals with above-average longevity, it may be possible to identify drugs with unrecognized health-promoting effects that support healthy aging and extend lifespan.

Recent studies have highlighted the influence of the human microbiome on a wide range of age-related diseases, including cardiovascular [1], metabolic [2], malignant [3] and neurodegenerative disorders [4,5]. Medications capable of modulating the microbiome—particularly through the elimination of specific pathogens—may therefore confer long-term health benefits that extend beyond their original therapeutic purposes.

Electronic health records (EHRs) from large healthcare organizations offer a powerful resource for systematically evaluating the long-term effects of medications on population health [6–8]. In this study, we utilized EHR data from Leumit Health Services (LHS), a nationwide healthcare provider in Israel, to conduct a comprehensive medication-wide association study. We constructed a matched cohort comparing individuals who exceeded the average lifespan and were still alive at follow-up with matched individuals who died before reaching the average life expectancy. Our goal was to identify medications associated with reduced all-cause mortality and increased longevity.

Our systematic screen identified two antiprotozoal agents—atovaquone-proguanil (A-P) and mefloquine—as being strongly and statistically significantly associated with increased longevity. Both compounds are antimalarials typically prescribed for short-term prophylaxis in travelers. Since malaria

is not endemic in Israel and these medications lack known targets in human cells, we sought to explore potential mechanisms by which they might reduce mortality and promote overall health. To this end, we constructed a historical cohort of LHS members who had purchased either medication and compared them to a matched cohort without such purchases, prospectively assessing the incidence of common age-related medical conditions. In addition to reduced mortality, individuals exposed to A-P or mefloquine exhibited significantly lower rates of a wide range of age-related morbidities, notably diabetes mellitus, cardiovascular and cerebrovascular disease, dementia, renal insufficiency, liver disease, pulmonary disease, and malignancy. Conversely, these protective associations were accompanied by significantly increased rates of specific adverse outcomes, particularly hearing loss, Sjögren's syndrome (eye dryness), and lichen planus, as well as a trend toward an increased rate of retinal detachment.

To validate these findings, we replicated the analysis in the U.S.-based TriNetX federated network, which aggregates electronic health records from over 120 million individuals. Using prospective cohorts rigorously matched for demographic characteristics and clinical risk factors, we evaluated associations for atovaquone-proguanil (A-P), mefloquine, and nirmatrelvir-ritonavir (N-R) —a medication with antiprotozoal properties that has been widely used over the past three years to prevent complications in individuals infected with COVID-19. For all three medications, we observed consistent patterns of highly significant reductions in all-cause mortality and in the incidence of age-related conditions, mirroring the associations identified in the LHS cohort. These findings included a robust reduction in mortality along with consistent, concordant changes in the incidence of age-related diseases.

Methods

Study design

The first stage of this research was conducted as a retrospective cohort study within Leumit Health Services (LHS), one of four nationwide health providers in Israel, delivering comprehensive

healthcare to approximately 730,000 members. All Israeli citizens are entitled to comprehensive health insurance and receive a standardized package of healthcare services and medications, as defined by the national “Health Basket” committee. LHS operates a centralized electronic health record (EHR) system, maintaining over two decades of meticulously curated data, including patient demographics, medical diagnoses, healthcare encounters, laboratory test results, and records of prescribed medications. In addition, LHS maintains a comprehensive network of affiliated pharmacies, enabling reliable tracking of medication purchases by its members—including over-the-counter medications—which allows for the identification of associations between medication uptake and clinical outcomes.

Cohort eligibility included current and former LHS members with electronic records of medical visits occurring after the age of 60. Data were extracted from the LHS central data warehouse, encompassing diagnoses and medication purchases through December 31, 2024. Structured query language (SQL) and Python scripts were used to automate data retrieval. Socioeconomic status (SES) was determined based on geocoded residential addresses and classified on a 1-20 scale using the Points Location Intelligence® database, which correlates strongly with official national SES indicators.

Using sex-specific longevity thresholds derived from median life expectancy in our health system—84 years for females and 77 years for males—we constructed two groups of eligible individuals: a high-longevity group, comprising individuals who exceeded the cutoff and were alive at follow-up, and a below-average longevity group, comprising individuals who died before reaching the respective cutoff age. For each individual who died before the threshold, we matched a control with above-average longevity based on sex, birth year, socioeconomic status (SES) group, and year of enrollment in LHS. Matching prioritized individuals with the closest birth dates, ensuring each control was matched to a single case. The index date was defined as the ambulatory visit occurring ten years after the first available EHR record for each individual.

We systematically compared the exposure rates for every medication provided within our health system during the decade preceding the index date. Medications were identified by their Anatomical Therapeutic Chemical (ATC) classification, and for each ATC class, exposure rates were compared between the above-average and below-average longevity groups using Fisher's exact test, with the false discovery rate (FDR) procedure applied to correct for multiple testing.

This systematic screen identified two antiprotozoals—A-P and mefloquine—as the medications most significantly associated with increased longevity. To investigate which disease reductions might underlie the observed association with decreased mortality, we constructed a cohort of individuals aged 40 to 85 who had received at least one prescription for either medication and matched them to 20 control patients of the same sex, age, socioeconomic status (SES) group, and year of first LHS membership. Matching prioritized individuals with the closest birth dates. The index date was defined as the first recorded exposure to the respective medication for the case group and was assigned to the matched controls. We then compared all-cause mortality and the incidence of a predefined set of age-related conditions between the two groups using Kaplan-Meier estimators and Cox proportional hazards models. Follow-up was censored at the date of death or at the date of the last recorded medical encounter for individuals who remained alive. Individuals with a documented diagnosis of a given condition prior to the index date were excluded from the respective analyses.

TriNetX Validation Cohort

Validation analyses were conducted using TriNetX, a federated research network comprising electronic health record (EHR) data from 69 U.S. healthcare organizations, covering over 120 million patients. Validation cohorts included individuals currently aged 70 to 89, and who had an ambulatory visit, which served as the index date. Eligibility required documentation of BMI prior to the index visit to allow for rigorous matching on BMI. Cases were defined as individuals who had received a

prescription for the medication of interest, while controls were selected from individuals with no record of such use.

Propensity score matching (PSM) was applied to balance groups on age, sex, ethnicity, race, smoking status, diabetes diagnosis, BMI, and HbA1c levels at baseline. Outcomes were compared using Kaplan-Meier survival curves and Cox proportional hazards models. Guided by the observed associations in LHS, we evaluated the following outcomes:

- **All-cause mortality**
- **Diabetes** (ICD-10: E08-E13; or incident HbA1c ≥6.5%)
- **Dementia** (F03, G30)
- **Renal insufficiency** (eGFR [MDRD] <45 mL/min/1.73 m^2)
- **Hepatic failure** (K72)
- **Congestive heart failure (CHF)** (I50)
- **Myocardial infarction (MI)** (I21)
- **Malignancies**: gastrointestinal (C15-C26), urinary tract (C64-C68), brain (C71), lung (C30-C39)
- **Chronic Obstructive Pulmonary Disease (COPD)** (J43-J44)
- **Hearing loss** (H90-H91)
- **Sjögren's syndrome** (M35.0)
- **Retinal detachment** (H33)
- **Lichen planus** (L43)

Follow-up was censored at the date of the last recorded medical encounter, up to 4000 days (~11 years) after the index date. For each outcome, individuals with a documented diagnosis prior to the index date were excluded from the corresponding analysis.

Data processing

Data from LHS were extracted from EHRs and processed using Python 3.11 scripts and T-SQL queries developed by the Leumit Research Institute. Patient identifiers were removed and replaced with study-specific codes to ensure anonymity. Medication use was assessed based on purchase records up to 10 years before the index date, classified by Anatomical Therapeutic Chemical (ATC) codes.

Statistical analyses

Analyses of LHS data were conducted using R version 4.4. Fisher's exact test was used for categorical variables, and two-tailed t-tests were applied for continuous variables. The log-rank test was used to compare survival between treatment groups. All tests were two-tailed, and P-values below 0.05 were considered statistically significant.

Ethics Statement

The study was reviewed and approved by the Leumit Health Services Institutional Review Board (IRB). Ethical approval was granted, with a waiver of informed consent (LEU-0020-24). The LHS data were fully de-identified prior to access and analysis for this study. All LHS data were analyzed retrospectively and anonymously under IRB approval.

Results

The study cohort

Table 1 summarizes the demographic and clinical characteristics of 14,986 patients with below-average longevity and 14,986 matched controls with above-average longevity in the LHS cohort. For convenience, we define individuals with the adverse outcome (death) as cases, as the purpose of this analysis is to identify compounds that reduce all-cause mortality. Due to the matching process, age, sex, and socioeconomic status distributions were similar between groups (49.2% female, mean age 71.0 ± 5.9 years at index date). Compared to controls, case patients had a slightly higher BMI (29.1 ± 6.0 vs. 28.5 ±

4.8 kg/m²) and weight (77.5 ± 17.7 vs. 76.3 ± 14.6 kg) and were more likely to be smokers (OR 2.00 [95% CI, 1.86-2.15]). At the end of follow-up (mean duration ~12.5 years), the average age of control individuals was 83.6 ± 5.9 years, while case patients died at an average age of 74.3 ± 5.7 years (Table 1B).

Medications associated with decreased mortality

Medication use over the preceding decade was systematically assessed for associations with decreased mortality. Table 2 presents the two medications that met the criterion of FDR < 5% (Benjamini-Hochberg correction). Both are antiprotozoal compounds, and were found to be significantly associated with decreased mortality: mefloquine (OR 0.32 [95% CI, 0.15-0.65], FDR = 0.0001) and A-P (OR 0.43 [95% CI, 0.27-0.69], FDR = 0.0002).

To better assess their effect on overall mortality and investigate which disease reductions underlie the observed increase in lifespan, we constructed a cohort of individuals aged 40 to 85 who had received at least one prescription for either A-P or mefloquine and matched each case to 20 control patients of the same sex, socioeconomic status (SES) group, and year of first LHS membership. The final cohort included 3,876 treated individuals and 77,820 matched controls with comparable baseline characteristics (Table 3). The mean age in both groups was 56.3 years, with 52.3% female participants in each group. Small but statistically significant differences were observed at baseline for BMI (27.0 ± 4.5 vs. 27.5 ± 5.2 kg/m², $p < 0.001$), weight (76.3 ± 15.3 kg in cases vs. 77.3 ± 16.5 kg in controls, $p < 0.001$), and height (168 ± 9 cm vs. 167 ± 10 cm, $p < 0.001$). Systolic blood pressure was similar across groups, while diastolic blood pressure was slightly lower in the treated group (76.8 ± 10.1 vs. 77.5 ± 9.0 mmHg, $p < 0.001$). Notably, treated individuals were significantly less likely to be current smokers (14.5% vs. 21.8%, $p < 0.001$) while past smoking rates were similar between groups. Ethnic group distributions did not differ between cases and controls.

Using Cox proportional hazards models, we assessed the association between treatment with A-P or mefloquine and the incidence of mortality and age-related comorbidities, with cumulative incidence plots displayed in Figure 1. Treated individuals exhibited a significantly lower all-cause mortality (HR = 0.40 [95% CI, 0.34-0.47], $p < 10^{-200}$; Figure 1A). Significant reductions were also observed for dementia (HR = 0.52 [0.41-0.67], $p < 10^{-6}$; Figure 1B), diabetes mellitus (HR = 0.83 [0.75-0.92], p = 0.0006; Figure 1C), heart failure (HR = 0.76 [0.63-0.91], p = 0.006; Figure 1D), myocardial infarction (HR = 0.78 [0.66-0.92], p = 0.003; Figure 1E), hepatic failure (HR = 0.64 [0.43-0.95], p = 0.03; Figure 1F), chronic obstructive pulmonary disease (COPD) (HR = 0.73 [0.62-0.86], p = 0.0002; Figure 1G), gastrointestinal malignancy (HR = 0.70 [0.52-0.96], p = 0.03; Figure 1H), and lung cancer (HR = 0.52 [0.33-0.82], p = 0.004; Figure 1I).

Conversely, treated individuals exhibited significantly increased risks of hearing loss (HR = 1.25 [1.14-1.37], $p < 10^{-5}$; Figure 1J), Sjögren's disease/eye dryness (HR = 1.25 [1.14-1.38], $p < 10^{-5}$; Figure 1K), and lichen planus (HR = 1.54 [1.03-2.31], p = 0.03; Figure 1L).

These results are summarized in a forest plot (Figure 2), which illustrates the hazard ratios for mortality and major age-related conditions associated with treatment using A-P or mefloquine. These findings suggest that treatment with these antiprotozoal agents is associated with broad reductions in age-related morbidity and mortality while increasing the risk of specific auditory, ophthalmic, and dermatologic conditions.

Validation in the US-based trinetX collaborative network.

To validate the associations observed in the national cohort, we conducted an independent analysis using TriNetX, a global federated network comprising EHRs from over 69 U.S. healthcare organizations and more than 120 million patients. From this population, we defined matched cohorts for A-P and mefloquine exposure, focusing on individuals currently aged 70 to 89. Cases were defined as

individuals who had received the medication of interest, while controls had no record of such use. Propensity score matching (PSM) was applied to balance groups on age, sex, ethnicity, race, smoking status, diabetes diagnosis, BMI, and HbA1c levels at baseline.

For additional validation and increased statistical power, we included a third cohort of individuals exposed to N-R (nirmatrelvir-ritonavir, Paxlovid), selected due to its predicted antiprotozoal properties and widespread use as a COVID-19 antiviral over the past three years. Compared to the smaller A-P and mefloquine cohorts, the N-R cohort provided substantially greater statistical power; however, due to the recent deployment of this medication, outcome assessment was limited to a maximum of three years post-exposure, in contrast to the longer follow-up available for the other two cohorts.

The final matched cohorts included 24,498 exposed individuals and 24,498 controls for A-P, 3,400 exposed individuals and 3,400 controls for mefloquine, and 124,681 exposed individuals and 124,681 controls for N-R (Table 4). Across all cohorts, the mean age at the index date was closely matched, with 69.0 ± 5.8 years for A-P, 67.6 ± 6.2 years for mefloquine, and 75.0 ± 5.5 years for N-R. Sex distributions were balanced across cohorts, with approximately 55% female for A-P, 52% for mefloquine, and 58% for N-R. Race and ethnicity distributions were similar between exposed individuals and controls within each cohort, with the majority identified as White (83% for A-P, 56% for mefloquine, and 85% for N-R). Baseline rates of nicotine dependence (3-8%), diabetes mellitus (14-26%), and overweight or obesity diagnoses (13-27%) were also comparable between exposed individuals and controls within each cohort. HbA1c levels and BMI were closely matched, ensuring well-balanced baseline metabolic profiles for subsequent outcome analyses.

In these three TriNetX cohorts, we compared mortality rates and the incidence of age-related conditions, guided by the associations discovered in the LHS cohort, excluding individuals with a prior diagnosis of each outcome before the index date. The results, presented in the cumulative incidence plots of Figure 3,

demonstrated consistent and significant reductions in all-cause mortality across cohorts: HR = 0.26 (95% CI, 0.24-0.28; $p < 10^{-3}$) for A-P, HR = 0.33 (0.27-0.40; $p < 10^{-3}$) for mefloquine, and HR = 0.50 (0.48-0.52; $p < 10^{-3}$) for N-R.

Significant reductions were also observed for dementia (HR = 0.48-0.64 across medications), diabetes—both as a clinical diagnosis (HR = 0.56-0.75) and defined by first occurrence of HbA1c ≥ 6.5% (HR = 0.57-0.68)—and kidney disease, defined as an eGFR below 45 mL/min/1.73 m^2 (HR = 0.53-0.71). Additional reductions were noted for heart failure (HR = 0.55-0.75), myocardial infarction (HR = 0.55-0.89), hepatic failure (HR = 0.28-0.48), chronic obstructive pulmonary disease (COPD; HR = 0.45-0.69), lung cancer (HR = 0.47-0.69), gastrointestinal malignancies (HR = 0.56-0.70), and brain malignancies (HR = 0.63 for A-P and N-R). All p-values were highly significant ($p < 0.05$, many $< 10^{-}$).

Conversely, as observed in the LHS cohort, exposure to these medications was associated with increased incidence of specific adverse outcomes: hearing loss (HR = 1.53-1.65), Sjögren's syndrome/dry eye (HR = 1.50-2.11), retinal detachment (HR = 1.34-2.01 for A-P and N-R), and lichen planus (HR = 1.59-1.73 for A-P and N-R). These findings across independent, large-scale cohorts reinforce the association of antiprotozoal exposure with broad reductions in age-related morbidity and mortality, while highlighting consistent increases in specific auditory and ophthalmic risks.

Discussion

In this study, we leveraged comprehensive electronic health records from large-scale healthcare networks in two countries to systematically screen for medications associated with increased human lifespan. Using a medication-wide association approach in a national Israeli cohort, we identified two antiprotozoal agents, A-P and mefloquine, as strongly and significantly associated with reduced all-cause mortality and a broad spectrum of age-related morbidities. These findings were independently

validated in the U.S.-based TriNetX network, where consistent reductions in mortality and major age-related outcomes were observed for these medications, as well as for N-R—a medication widely used during the COVID-19 pandemic that contains ritonavir, which has known antiprotozoal activity.

The novelty of this work lies in its design: by systematically comparing medication histories over a decade in individuals with above- versus below-average longevity within a large population, we identified a class of medications—antiprotozoals—that consistently exhibit strong associations with increased lifespan and a reduced incidence of common life-shortening conditions, including diabetes and its complications, cardiovascular and cerebrovascular diseases, chronic kidney disease, hepatic failure, chronic obstructive pulmonary disease, dementia, and various malignancies. Replicating these associations across two independent healthcare systems in different countries, and for three mechanistically related but distinct medications, provides compelling evidence for the robustness of these findings.

These results raise the possibility that many age-related conditions with incompletely understood etiologies may, at least in part, be driven by unrecognized, chronic protozoal colonization, which may represent a ubiquitous and overlooked contributor to chronic inflammation, immune dysregulation, and tissue damage underlying the biology of aging. Reduction of protozoal load through short-course antiprotozoal therapy may confer long-term health benefits, as observed in both cohorts.

Remarkably, we also observed consistent increases in the incidence of certain adverse outcomes, including hearing loss, Sjögren's syndrome[9], and lichen planus[10], following antiprotozoal exposure. Rather than undermining the protective associations, these findings provide key mechanistic insights and further strengthen the plausibility of our results. These conditions affect cell types and tissues that are highly sensitive to localized immune-mediated damage, which may arise following the pharmacological elimination of intracellular pathogens. The abrupt clearance of these pathogens could trigger localized

inflammation and immune activation at sites of prior intracellular colonization, revealing the pathogen reservoirs while concurrently reducing systemic inflammation.

A key question is which pathogen's elimination could underlie these associations.. Based on global seroprevalence, tissue tropism, and epidemiological links to neurodegenerative and cardiovascular diseases, we hypothesize that *Toxoplasma gondii* is the primary culprit. As an intracellular parasite, *T. gondii* can colonize the gut, disseminate hematogenously, establish low-grade infections in various tissues, including in the CNS, often evading immune detection. Its presence has been associated with increased risks of dementia[11], schizophrenia[12], and cardiovascular diseases[13], while our findings of reduced diabetes and its complications following antiprotozoal treatment align with the hypothesis that eradication of chronic *T. gondii* infection may mitigate systemic inflammation and thromboembolic risks.

From an evolutionary perspective, it makes perfect sense that *T. gondii* would have developed mechanisms to weaken and accelerate the senescence of its intermediate hosts, thereby increasing the likelihood that they fall prey to felines, its definitive hosts where sexual replication occurs. *T. gondii* has been shown to use sophisticated strategies to hijack neuronal pathways in rodents, diminishing fear responses and facilitating predation by cats [14,15]. In this context, it is plausible that the parasite has also evolved strategies that reduce physical fitness and impair systems essential for long-term survival—such as metabolic, cardiovascular, renal, and hepatic systems—thereby further increasing the chances that fully grown intermediate hosts are captured by feline predators. Such weakening would enhance the parasite's transmission opportunities, aligning with its evolutionary strategy. Humans, as accidental hosts, may suffer the same harms, and *T. gondii* may contribute to aging-related morbidity and mortality as unintended consequences of its adaptive strategy in natural hosts.

T. gondii is ubiquitous in human environments, with global seroprevalence estimates ranging from 20% to 80% depending on geography and age. The longer individuals live, the greater their

cumulative likelihood of environmental exposure and eventual parasitic colonization, even in the absence of overt clinical disease. As an intracellular parasite, *T. gondii* initially colonizes the gastrointestinal tract, where it may induce chronic low-grade inflammation and promote local immune evasion. By interfering with host cell apoptosis and modulating immune surveillance, *T. gondii* may increase the risk of malignancy. Supporting this, we have shown in a recent study that *T. gondii* DNA signatures are enriched in the stool of individuals with colorectal cancer, indicating active or latent gut colonization in these patients [16].

Additionally, *T. gondii* can colonize the skin (Leyva and Santa Cruz, 1986), which is anatomically contiguous with the gastrointestinal outlet. While cutaneous toxoplasmosis is typically associated with immune deficiency, it is likely that low-grade, localized colonization of the skin or mucous membranes occurs more broadly, particularly in aging individuals with declining immune surveillance. Such colonization may contribute to chronic, non-specific inflammation and insulin resistance, a hallmark of diabetes mellitus—a condition we found to be significantly reduced following antiprotozoal treatment. Notably, *T. gondii* infections that remain localized without systemic dissemination may not trigger detectable serological responses, consistent with the parasite's intracellular lifestyle and immune evasion strategies. Supporting this hypothesis, several studies have reported increased *T. gondii* seroprevalence among individuals with diabetes mellitus [17,18].

Furthermore, *T. gondii* is capable of systemic dissemination via hematogenous spread, allowing it to reach and infect a wide range of cell types, notably neuronal tissue within the central nervous system (CNS). Increased seropositivity for *T. gondii* has been associated with a range of neuropsychiatric and neurodegenerative conditions, including dementia and schizophrenia, aligning with our observation of reduced dementia incidence following antiprotozoal treatment [19–24].

Parasite dissemination into the systemic circulation may precipitate thromboembolic phenomena, a proposed mechanism for the association of *T. gondii* with cardiovascular and cerebrovascular

morbidity [13,25]. The marked reductions in myocardial infarction and stroke observed following antiprotozoal treatment in our study are consistent with this hypothesis, suggesting that protozoal eradication may mitigate thromboembolic risk by reducing systemic parasite burden and associated vascular inflammation.

Supporting evidence that A-P, mefloquine, and N-R (Paxlovid) possess anti-*Toxoplasma* activity further strengthens the plausibility of our hypothesis.

Atovaquone is a well-established anti-*Toxoplasma* agent that inhibits the parasite's mitochondrial electron transport chain, impairing its energy production and replication. It is used in combination therapies for toxoplasmosis treatment and prophylaxis, with demonstrated efficacy in suppressing and clearing *T. gondii* infections, including in immunocompromised patients. Proguanil, while primarily targeting *Plasmodium*, may enhance atovaquone's efficacy by additional mitochondrial inhibition and by inhibiting dihydrofolate reductase (DHFR), thereby interfering with folate metabolism, which is also required for *T. gondii* survival and replication.[26,27]

Mefloquine is an antiprotozoal widely used for malaria prophylaxis and treatment, particularly against *Plasmodium falciparum* strains resistant to chloroquine and other first-line antimalarials. Importantly, mefloquine has demonstrated both in vitro and in vivo activity against *T. gondii*[28,29]. Animal studies have shown reduced parasite loads and extended survival in infected mice treated with mefloquine, indicating its ability to target *T. gondii* tissue cysts and tachyzoites through interference with parasite autophagy and disruption of membrane stability. Additionally, mefloquine is thought to impair parasite autophagic pathways and mitochondrial function, further contributing to its efficacy against intracellular protozoa, including *T. gondii*.

Lastly, N-R (Paxlovid) has not been formally studied for *T. gondii* activity; however, ritonavir and related HIV protease inhibitors have demonstrated *in vitro* anti-*Toxoplasma* activity, likely by interfering with the parasite's protease systems and replication cycles[30,31]. Furthermore, protease

inhibitors have been investigated for synergistic effects with other anti-*Toxoplasma* agents, supporting their potential role in suppressing *T. gondii* replication.

Medications used for malarial prophylaxis are typically administered for the duration of travel (generally several weeks). Combined with their high intracellular penetration, this treatment period may be sufficient to eliminate or clear a substantial portion of the *T. gondii* burden in the host. By reducing parasite load below a critical threshold, such treatments could enable the immune system to prevent the re-expansion of subclinical foci. This mechanism may underlie the durable reductions in chronic inflammation and the lowered risk of age-related diseases that we observed in both populations, persisting for up to a decade after exposure.

In contrast, N-R is administered for only five days to prevent COVID-19 complications—a much shorter exposure than typical antimalarial regimens—which may limit its effectiveness in eradicating *T. gondii*. This shorter treatment duration, combined with potentially lower potency against *T. gondii*, may result in only partial suppression of the parasite, allowing residual organisms to persist and eventually recolonize the host over time. This mechanism could explain why the strong protective associations observed shortly after N-R exposure appear to wane in our analyses, compared to the more durable protective effects seen with A-P and mefloquine.

The observed associations of antiprotozoal treatments with hearing loss, retinal detachment, Sjögren's syndrome, and lichen planus further strengthen the biological plausibility of *T. gondii* involvement. These associations align with the known tropism of *T. gondii* for these anatomical sites, as demonstrated by congenital toxoplasmosis being a leading cause of sensorineural hearing loss in congenitally infected infants [32] and by studies linking toxoplasma seropositivity to hearing loss[33]; by toxoplasma retinitis, which is the most common cause of posterior uveitis globally [34]; and by cutaneous toxoplasmosis, which frequently manifests in immunocompromised individuals [35]. Together, these observations suggest that increases in specific localized conditions following antiprotozoal treatment

may reflect the eradication of *T. gondii* from its natural reservoirs, thereby triggering tissue-specific pathology while simultaneously reducing the risk of further spread.

Together, these pharmacologic and epidemiologic observations support a paradigm-shifting hypothesis: chronic toxoplasma colonization may contribute to a wide range of age-related conditions, and targeted eradication could reduce both mortality and morbidity. Specifically, we propose that short-course antiprotozoal therapies may promote healthy aging and lower age-related disease risks by reducing the burden of *T. gondii* in humans. These insights pave the way for further investigation into targeted antimicrobial interventions as a strategy to slow aging processes and extend human lifespan by clearing persistent *T. gondii* reservoirs within the body, while minimizing the collateral cell-mediated damage in sensitive tissues—including auditory and ophthalmic pathways—that may accompany parasite elimination.

Despite the strengths of our large-scale, systematically matched analyses and replication across independent populations, this study has several limitations. First, as an observational study, it is impossible to rigorously exclude residual confounding, even though we employed extensive matching for demographic factors to reduce this risk. In the LHS cohort, individuals exposed to antimalarial medications exhibited slightly healthier baseline characteristics, including lower BMI and reduced smoking rates, which may explain part, though not all, of the risk reduction.

In contrast, the validation analyses in the TriNetX population included rigorous matching for both demographic and clinical factors, including ethnicity, BMI, diabetes status, HbA1c range, and smoking status, making clinical confounding less likely in this setting. While some confounding by indication may occur, given that antimalarials are typically prescribed to individuals able and willing to travel internationally, the presence of consistent protective associations for N-R—a medication administered to patients infected with COVID-19 and at risk of severe disease—argues against confounding. Individuals treated with N-R are typically less healthy, and present higher risk factors for

severe COVID-19. During the study period in the United States, this medication was widely available at no cost under federal programs, ensuring access across socioeconomic groups and reducing the potential for bias due to socioeconomic status. Additionally, the persistence of protective associations for up to a decade after exposure, and across conditions such as malignancy and myocardial infarction that frequently occur in individuals who appear otherwise healthy until shortly before diagnosis, further argues against confounding as the primary driver of these observations. Nonetheless, further prospective and mechanistic studies will be essential to confirm causality and elucidate the underlying biological mechanisms.

Until now, the prevailing view has been that *T. gondii* is largely innocuous in humans, except for its teratogenic effects in newly infected pregnant women and its impact on immunocompromised individuals. Consequently, serological testing is rarely conducted outside these contexts. In histopathological examinations, even when the small, easily overlooked cysts characteristic of intracellular *T. gondii* are present, they are often disregarded or unreported due to the absence of an immediately recognized clinical association. This may explain why the long-term harmful effects of *T. gondii* have remained underrecognized and why therapeutic interventions targeting its elimination have not been explored in immunocompetent individuals.

Conclusion

Overall, the protective effects of antiprotozoal medications against mortality and a wide range of aging-associated diseases observed in populations from two countries support the hypothesis that protozoal colonization—most likely *Toxoplasma gondii*—may be a major contributor to a broad spectrum of age-related conditions, including metabolic, cardiovascular, cerebrovascular, neurodegenerative, and malignant diseases. Our findings raise the possibility that targeted eradication or suppression of protozoal infections could represent a novel and promising intervention to reduce age-

related morbidity, significantly lower overall mortality, and promote healthy aging. These findings warrant confirmation in prospective trials.

References

1. Wang, T. *et al.* Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk. *Nat Med* **30**, 1722–1731 (2024).
2. Afzaal, M. *et al.* Human gut microbiota in health and disease: Unveiling the relationship. *Front Microbiol* **13**, (2022).
3. Sun, J. *et al.* Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation. *NPJ Biofilms Microbiomes* **11**, 43 (2025).
4. Toh, T. S. *et al.* Gut microbiome in Parkinson's disease: New insights from meta-analysis. *Parkinsonism Relat Disord* **94**, 1–9 (2022).
5. Zhou, K., Baranova, A., Cao, H., Sun, J. & Zhang, F. Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization. *Schizophrenia* **10**, 75 (2024).
6. Israel, A. *et al.* Type 2 Diabetes in Patients with G6PD Deficiency. *New England Journal of Medicine* **391**, 568–569 (2024).
7. Israel, A. *et al.* Identification of drugs associated with reduced severity of covid-19 – a case-control study in a large population. *Elife* **10**, (2021).
8. Israel, A. *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. *The BMJ* **375**, e067873 (2021).
9. Negrini, S. *et al.* Sjögren's syndrome: a systemic autoimmune disease. *Clin Exp Med* **22**, 9–25 (2022).
10. Le Cleach, L. & Chosidow, O. Lichen Planus. *New England Journal of Medicine* **366**, 723–732 (2012).

11. Yang, H.-Y. *et al.* Risk of dementia in patients with toxoplasmosis: a nationwide, population-based cohort study in Taiwan. *Parasit Vectors* **14**, 435 (2021).

12. Sutterland, A. L. *et al*. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta□analysis. *Acta Psychiatr Scand* **132**, 161–179 (2015).

13. Egorov, A. I. *et al.* Latent Toxoplasma gondii infections are associated with elevated biomarkers of inflammation and vascular injury. *BMC Infect Dis* **21**, 188 (2021).

14. Webster, J. P. The Effect of Toxoplasma gondii on Animal Behavior: Playing Cat and Mouse. *Schizophr Bull* **33**, 752–756 (2007).

15. Vyas, A., Kim, S.-K., Giacomini, N., Boothroyd, J. C. & Sapolsky, R. M. Behavioral changes induced by *Toxoplasma* infection of rodents are highly specific to aversion of cat odors. *Proceedings of the National Academy of Sciences* **104**, 6442–6447 (2007).

16. Israel, A. *et al.* Atovaquone-Proguanil and Reduced Digestive Cancer Risk: A *Toxoplasma gondii* Connection. Preprint at https://doi.org/10.1101/2025.03.24.25324497 (2025).

17. Soltani, S. *et al*. The Probable Association between Chronic Toxoplasma gondii Infection and Type 1 and Type 2 Diabetes Mellitus: A Case-Control Study. *Interdiscip Perspect Infect Dis* **2021**, 1–6 (2021).

18. Catchpole, A. *et al.* Association between Toxoplasma gondii Infection and Type-1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* **20**, 4436 (2023).

19. Flegr, J. Effects of Toxoplasma on Human Behavior. *Schizophr Bull* **33**, 757–760 (2007).

20. Nayeri, T., Sarvi, S., Sharif, M. & Daryani, A. Toxoplasma gondii: A possible etiologic agent for Alzheimer's disease. *Heliyon* **7**, e07151 (2021).

21. Torrey, E. F., Bartko, J. J. & Yolken, R. H. Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update. *Schizophr Bull* **38**, 642–647 (2012).

22. Wang, J. *et al.* Analysis of the Correlation Between Toxoplasma gondii Seropositivity and Alzheimer's Disease. *Pathogens* **13**, 1021 (2024).

23. Wiener, R. C., Waters, C. & Bhandari, R. The association of Toxoplasma gondii IgG and cognitive function scores: NHANES 2013–2014. *Parasitol Int* **78**, 102123 (2020).

24. Israel, A. *et al.* Atovaquone/Proguanil Use and Zoster Vaccination Are Associated with Reduced Alzheimer's Disease Risk in Two Cohorts: Implications for a Latent *Toxoplasma gondii* Mechanism. Preprint at https://doi.org/10.1101/2025.03.07.25323566 (2025).

25. Alhusseiny, S. M., Saleh, N. E., El-Zayady, W. M., Hussein, M. S. & El-Beshbishi, S. N. Association between *Toxoplasma gondii* infection and coronary atherosclerosis. *Trans R Soc Trop Med Hyg* **115**, 1190–1197 (2021).

26. Spencer, C. M. & Goa, K. L. Atovaquone. *Drugs* **50**, 176–196 (1995).

27. KOVACS, J. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. *The Lancet* **340**, 637–638 (1992).

28. El Sharazly, B. M. *et al.* Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis. *Acta Trop* **239**, 106810 (2023).

29. Secrieru, A., Costa, I. C. C., O'Neill, P. M. & Cristiano, M. L. S. Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis—A Short Bridge between Two Distant Illnesses. *Molecules* **25**, 1574 (2020).

30. Alfonso, Y. & Monzote, L. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. *Open Med Chem J* **5**, 40–50 (2011).

31. Derouin, F. & Santillana-Hayat, M. Anti- *Toxoplasma* Activities of Antiretroviral Drugs and Interactions with Pyrimethamine and Sulfadiazine In Vitro. *Antimicrob Agents Chemother* **44**, 2575–2577 (2000).

32. Boyer, K. M. *et al.* Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. *Am J Obstet Gynecol* **192**, 564–571 (2005).

33. Getzmann, S. *et al.* Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span. *Life (Basel)* **14**, (2024).

34. Holland, G. N. Ocular toxoplasmosis: a global reassessment. *Am J Ophthalmol* **136**, 973–988 (2003).

35. Leyva, W. H. & Santa Cruz, D. J. Cutaneous toxoplasmosis. *J Am Acad Dermatol* **14**, 600–605 (1986).

Footnotes

Conflicts of interest: Authors declare that they have no competing interests.

Funding Sources: This research was internally funded by Leumit Health Services (LHS). ER was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Consent Statement: Ethics approval was granted by the Leumit Health Services Institutional Review Board (LEU-0001-24), with a waiver of informed consent due to retrospective, anonymized data analysis.

Data Availability: Access to the LHS data used in this study are restricted to researchers approved by the LHS Institutional Review Board. The TriNetX data used in this study is limited to members of the TriNetX network.

Keywords: Healthy aging, longevity, atovaquone/proguanil, mefloquine, *Toxoplasma gondii*, dementia, diabetes, malignancy, renal disease, liver failure

Author contributions:

Conceptualization: AI, EMe, Ema

Methodology: AI, EMe

Investigation: AI, SI, Eme

Writing - original draft: AI

Writing - review & editing: AI, AW, SI, ER, SA, SV, EMa, EMe

Table 1. Demographic and clinical characteristics of the LHS exploratory cohort for longevity

A. at the index date

		Case N=14,986	Control N=14,986	P-value	Odds Ratio	SMD
Gender	Female	7,617 (50.8 %)	7,617 (50.8 %)	1.000	1	
	Male	7,369 (49.2 %)	7,369 (49.2 %)	1.000	1	
Age (years)		70.9 ± 5.9	71.0 ± 5.9	0.098		-0.019
Age category	**60-69**	6,311 (42.11 %)	6,244 (41.67 %)	0.433	1.02 [0.97 to 1.07]	
	70-79	7,303 (48.73 %)	7,317 (48.83 %)	0.881	1.00 [0.95 to 1.04]	
	80-89	1,372 (9.16 %)	1,425 (9.51 %)	0.293	0.96 [0.89 to 1.04]	
Weight (kg)		77.5 ± 17.7	76.3 ± 14.6	<0.001		0.076
Height (cm)		165 ± 10	164 ± 10	0.030		0.030
Body Mass Index (kg/m2)		29.1 ± 6.0	28.5 ± 4.8	<0.001		0.127
BP systolic (mmHg)		134 ± 20	133 ± 17	0.104		0.019
BP diastolic (mmHg)		76.8 ± 10.1	77.5 ± 9.0	<0.001		-0.079
Smoking status	Non-smoker	6,705 (73.6 %)	12,067 (84.3 %)	<0.001	0.52 [0.49 to 0.55]	
	Past smoker	485 (5.32 %)	562 (3.93 %)	<0.001	1.38 [1.21 to 1.56]	
	Smoker	1,919 (21.1 %)	1,684 (11.8 %)	<0.001	2.00 [1.86 to 2.15]	
Socio-economic status (1-20)		9.50 ± 3.14	9.55 ± 3.17	0.266		

B. at the end of follow-up

		Case N=14,986	Control N=14,986	P-value	Odds Ratio	SMD
Age (years)		74.3 ± 5.7	83.6 ± 6.5	<0.001		-1.213
Age category	**50-59**	7 (0.047 %)		0.016	Inf [1.44 to Inf]	
	60-69	3,051 (20.4 %)		<0.001	Inf [1050.26 to Inf]	
	70-79	8,529 (56.9 %)	4,639 (31.0 %)	<0.001	2.95 [2.81 to 3.09]	
	80-89	3,399 (22.7 %)	7,516 (50.2 %)	<0.001	0.29 [0.28 to 0.31]	
	90-		2,831 (18.9 %)	<0.001	0.00 [0.00 to 0.00]	
died during period		14,986 (100 %)		<0.001	Inf [8402.05 to Inf]	

Panel A shows characteristics at the index date, comparing individuals who died before reaching the median life expectancy (cases) with matched individuals who survived beyond it (controls). Panel B shows characteristics at the end of follow-up. Continuous variables are presented as mean ± standard deviation. Categorical variables are presented as counts and percentages. P-values are from two-tailed t-tests (continuous) or Fisher's exact tests (categorical). Odds ratios (OR) with 95% confidence intervals represent the association with case status. Standardized mean differences (SMD, Cohen's D) quantify effect size

Table 2. Comparison of medication purchases in the 10 years preceding the index date in the case (shorter lifespan) and control (longer lifespan) groups of the LHS cohort

Medication	Case N=14,986	Control N=14,986	Odds Ratio [95% CI]	p-value	FDR
Mefloquine	11 (0.07%)	34 (0.23%)	0.32 [0.15-0.65]	0.00082	0.0001
Atovaquone + Proguanil	27 (0.18%)	62 (0.41%)	0.43 [0.27-0.69]	0.00026	0.0002

Counts and percentages reflect the number of individuals in each group who purchased the listed medications. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using Fisher's exact test, with associated p-values and false discovery rate (FDR)–adjusted p-values provided. Only medications meeting the FDR threshold for significance are shown. PO: oral administration; SC: subcutaneous; IM: intramuscular.

Table 3. Demographic and clinical characteristics of the LHS cohort of individuals treated with atovaquone-proguanil or mefloquine vs. matched controls

		Case N=3,876	Control N=77,820	P-value	Odds Ratio	SMD
Gender	Female	2,028 (52.3 %)	40,560 (52.3 %)	1.000	1	
	Male	1,848 (47.7 %)	36,960 (47.7 %)	1.000	1	
Age (years)		56.3 ± 9.4	56.3 ± 9.6	0.990	1.02 [0.95 to 1.10]	0.000
Age category	**40-49**	1,100 (28.4 %)	21,624 (27.9 %)	0.509	0.92 [0.86 to 0.99]	
	50-59	1,325 (34.2 %)	27,903 (36.0 %)	0.023	1.11 [1.03 to 1.19]	
	60-69	1,111 (28.7 %)	20,594 (26.6 %)	0.004	1.02 [0.91 to 1.15]	
	70-79	326 (8.41 %)	6,389 (8.24 %)	0.697	0.27 [0.15 to 0.46]	
	80-89	14 (0.36 %)	1,010 (1.30 %)	<0.001	1.02 [0.95 to 1.10]	
Weight (kg)		76.3 ± 15.3	77.3 ± 16.5	<0.001		-0.060
Height (cm)		168 ± 9	167 ± 10	<0.001		0.079
Body Mass Index (kg/m2)		27.0 ± 4.5	27.5 ± 5.2	<0.001		-0.114
BP systolic (mmHg)		134 ± 20	133 ± 17	0.104		0.019
BP diastolic (mmHg)		76.8 ± 10.1	77.5 ± 9.0	<0.001		-0.079
Smoking status	Non-smoker	3,168 (82.8 %)	56,248 (75.3 %)	<0.001	1.58 [1.45 to 1.73]	
	Past smoker	105 (2.74 %)	2,181 (2.92 %)	0.587	0.94 [0.76 to 1.15]	
	Smoker	553 (14.5 %)	16,301 (21.8 %)	<0.001	0.61 [0.55 to 0.66]	
Ethnic group		88 (2.27 %)	1,760 (2.27 %)	1.000	1	
		3,591 (92.7 %)	71,820 (92.7 %)	1.000	1	
		197 (5.1 %)	3,940 (5.1 %)	1.000	1	

Counts and percentages represent the distribution of key demographic and clinical variables in treated individuals (cases) and matched controls at baseline. Odds ratios (OR) with 95% confidence intervals (CI) are provided for categorical variables, alongside p-values computed using Fisher's exact test. Continuous variables are presented as mean ± standard deviation, with standardized mean differences (SMD; Cohen's d) indicating effect sizes between groups. BP: blood pressure; BMI: body mass index.

Table 4. Demographic and clinical characteristics of the matched TriNetX cohorts for atovaquone-proguanil, mefloquine and nirmatrelvir-ritonavir exposure

		Atovaquone-proguanil	Mefloquine	Nirmatrelvir-ritonavir
N		24,498 / 24,498	3,400 / 3,400	124,681 / 124,681
Age at Index		69.0±5.8 / 69.0±5.9	67.6±6.2 / 67.7±6.3	74.9±5.2 / 75.0±5.5
Sex	Female	55.0% / 55.0%	52.0% / 52.5%	57.7% / 58.1%
	Male	45.0% / 45.0%	48.0% / 47.5%	42.3% / 41.9%
Race/Ethnicity	White	82.8% / 83.3%	55.4% / 56.2%	86.7% / 83.5%
	Black or African American	5.3% / 5.2%	15.7% / 15.4%	4.7% / 4.8%
	Hispanic or Latino	1.2% / 1.1%	1.3% / 1.0%	2.8% / 2.7%
	Not Hispanic or Latino	83.8% / 79.7%	82.5% / 78.0%	73.1% / 75.7%
	Asian	4.5% / 4.2%	13.4% / 13.3%	3.4% / 4.1%
	Other Race	1.6% / 1.8%	4.4% / 3.5%	1.9% / 2.5%
Nicotine dependence		3.5% / 3.3%	3.1% / 2.7%	7.9% / 7.5%
Diabetes mellitus		14.0% / 13.6%	22.3% / 21.9%	26.0% / 25.4%
Overweight or obesity (diagnosis)		14.4% / 14.3%	13.0% / 13.4%	26.8% / 25.6%
Hemoglobin A1c (%)		5.9±0.9 / 5.9±1.1	6.3±1.1 / 6.2±1.2	6.0±1.0 / 6.0±1.0
Hemoglobin A1c range	0-5.7 %	25.6% / 25.4%	15.9% / 15.7%	35.9% / 33.7%
	5.7-6.5 %	25.5% / 24.9%	27.1% / 26.5%	38.7% / 35.2%
BMI (kg/m^2)		26.8±4.8 / 26.8±4.9	27.4±4.9 / 27.2±5.1	28.2±5.9 / 28.2±5.8
BMI ranges (kg/m^2)	0-25	52.1% / 52.5%	46.4% / 47.0%	45.7% / 48.6%
	25-30	57.9% / 57.7%	57.4% / 57.8%	60.7% / 61.6%
	30-35	27.9% / 27.9%	30.5% / 30.1%	39.9% / 39.9%
	35-40	9.4% / 9.1%	10.0% / 9.4%	18.6% / 17.9%
	40-	3.4% / 3.2%	4.2% / 3.8%	8.7% / 8.6%

Values are presented as mean ± standard deviation (SD) for continuous variables and as percentages for categorical variables. For each variable, values before the slash correspond to the medication-exposed group, and values after the slash correspond to the propensity score-matched control group. Variables include demographics, comorbidities, and metabolic parameters relevant to baseline risk stratification across the three exposure cohorts.

Figure 1. Cumulative incidence plots of major health outcomes in patients treated with atovaquone-proguanil or mefloquine vs. Matched Controls in LHS



Kaplan-Meier curves showing cumulative incidence of major health outcomes in Leumit Health Services (LHS) patients treated with mefloquine or atovaquone-proguanil (red) compared to matched controls (blue). Hazard ratios (HR), 95% confidence intervals (CI), and *p*-values were estimated using Cox proportional hazards models. Follow-up was censored at the date of last recorded visit, and

individuals with the outcome at baseline were excluded from the respective analyses. Shaded areas indicate 95% CI. Panel labels: A: All-cause mortality; B: Dementia; C: Diabetes mellitus; D: Congestive heart failure (CHF); E: Myocardial infarction; F: Hepatic failure; G: Chronic Obstructive Pulmonary Disorder (COPD); H: Gastrointestinal (GI) malignancy; I: Lung malignancy; J: Hearing loss; K: Dry eye; L: Lichen planus

Figure 2. Forest plot of selected health outcomes in patients treated with atovaquone-proguanil or mefloquine vs. matched control in LHS



Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality and selected age-related conditions among patients treated with mefloquine or atovaquone-proguanil, compared to matched controls in Leumit Health Services (LHS). Outcomes were assessed using Cox proportional hazards models, with follow-up censored at the last recorded clinical encounter. Individuals with a preexisting diagnosis of the respective condition at the index date were excluded. Horizontal bars indicate 95% CIs; values to the left of 1 indicate reduced risk, and those to the right indicate increased risk. Significant protective associations were observed for mortality, dementia, diabetes, cardiovascular events, hepatic failure, COPD, and several malignancies. Conversely, treated individuals exhibited increased risk of hearing loss and dry eye, and lichen planus.

Figure 3. Cumulative incidence of mortality and age-related health outcomes following antiprotozoal exposure in TriNetX cohorts



E EGFR <45 in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	22,037	18,927	16,816	15,153	14,289	13,643	11,871	9,758	7,902
Control	20,823	15,926	13,868	11,966	10,392	8,958	7,610	6,332	5,230

EGFR <45 in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,060	2,730	2,466	2,242	2,097	2,007	1,830	1,607	1,368
Control	2,832	2,263	1,990	1,729	1,521	1,345	1,173	972	812

EGFR <45 in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	101,347	99,256	84,899	67,726	51,653	29,423	4,497
Control	97,798	88,003	78,013	69,250	61,323	53,228	49,531

F CHF in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,703	20,243	17,984	16,206	15,283	14,591	12,696	10,437	8,451
Control	22,781	17,194	14,973	12,919	11,220	9,672	8,216	6,836	5,646

CHF in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,290	2,816	2,544	2,312	2,163	2,070	1,888	1,657	1,411
Control	3,169	2,415	2,124	1,845	1,623	1,435	1,251	1,037	866

CHF in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	112,435	102,019	87,263	69,611	53,091	30,242	4,622
Control	108,142	92,513	82,012	72,799	64,466	55,957	52,070

G MI in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,956	21,128	18,771	16,914	15,951	15,229	13,251	10,893	8,821
Control	23,479	18,522	16,129	13,917	12,087	10,419	8,850	7,364	6,082

MI in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,313	2,965	2,679	2,435	2,277	2,180	1,988	1,745	1,486
Control	3,262	2,604	2,290	1,989	1,750	1,547	1,349	1,118	934

MI in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	118,040	107,388	91,855	73,274	55,885	31,833	4,865
Control	115,855	98,685	87,482	77,655	68,767	59,689	55,544

H Hepatic failure in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,435	21,826	19,391	17,473	16,478	15,733	13,689	11,253	9,112
Control	24,334	19,611	17,078	14,736	12,798	11,032	9,371	7,797	6,440

Hepatic failure in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,388	3,054	2,759	2,508	2,346	2,245	2,048	1,798	1,531
Control	3,373	2,734	2,404	2,089	1,837	1,624	1,417	1,174	981

Hepatic failure in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	124,313	111,813	95,640	76,293	58,187	33,145	5,066
Control	123,906	102,354	90,735	80,543	71,324	61,909	57,609

I COPD in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	23,628	20,723	18,410	16,590	15,645	14,937	12,997	10,684	8,652
Control	22,622	17,671	15,388	13,278	11,532	9,940	8,444	7,026	5,803

COPD in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,291	2,886	2,608	2,370	2,217	2,122	1,935	1,699	1,446
Control	3,189	2,508	2,206	1,916	1,686	1,490	1,300	1,077	900

COPD in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	108,807	105,996	90,664	72,325	55,160	31,421	4,802
Control	109,956	95,716	84,850	75,319	66,698	57,893	53,872

J Brain malignancy in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,470	21,910	19,465	17,540	16,541	15,793	13,742	11,296	9,147
Control	24,428	19,811	17,252	14,886	12,928	11,144	9,466	7,877	6,506

Brain malignancy in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,389	3,067	2,771	2,519	2,355	2,255	2,056	1,805	1,537
Control	3,389	2,775	2,441	2,120	1,865	1,649	1,438	1,192	996

Brain malignancy in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	124,453	112,151	95,929	76,524	58,363	33,245	5,081		
Control	124,463	102,998	91,306	81,049	71,772	62,298	57,971		

K GI malignancy in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,127	21,513	19,113	17,222	16,241	15,507	13,493	11,091	8,982
Control	23,936	19,175	16,698	14,408	12,513	10,786	9,162	7,624	6,297

GI malignancy in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,363	3,008	2,717	2,470	2,310	2,211	2,016	1,770	1,507
Control	3,319	2,696	2,371	2,060	1,812	1,602	1,397	1,158	967

GI malignancy in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	121,705	110,862	94,826	75,645	57,692	32,863	5,023		
Control	122,466	101,385	89,876	79,780	70,648	61,323	57,063		

L Lung malignancy in patients exposed to A-P



TriNetX Numbers at risk

Atovaq.	24,304	21,649	19,233	17,331	16,344	15,605	13,578	11,161	9,038
Control	24,145	19,327	16,830	14,522	12,612	10,872	9,235	7,684	6,347

Lung malignancy in patients exposed to mefloquine



TriNetX Numbers at risk

Mefloq.	3,376	3,033	2,740	2,491	2,330	2,230	2,034	1,785	1,520
Control	3,353	2,712	2,385	2,072	1,823	1,611	1,406	1,165	973

Lung malignancy in patients exposed to N-R



TriNetX Numbers at risk

Nirmat.	122,459	111,046	94,984	75,770	57,788	32,918	5,031		
Control	123,155	101,652	90,113	79,990	70,834	61,484	57,214		



Cumulative incidence curves comparing patients treated with atovaquone-proguanil (left), mefloquine (middle), and nirmatrelvir-ritonavir (right) versus propensity score-matched controls in the TriNetX network. Outcomes include all-cause mortality and selected age-related conditions identified in the LHS cohort, with follow-up extending up to eight years for atovaquone-proguanil and mefloquine and up to three years for nirmatrelvir-ritonavir. Patients with pre-existing diagnoses of the respective outcomes were excluded from each analysis. Hazard ratios (HRs), 95% confidence intervals (CIs), and p-values are shown for each comparison, demonstrating consistent reductions in mortality and morbidity across

multiple outcomes while identifying increased risks for specific adverse events, including hearing loss and ophthalmic conditions.